Dingke Medical Secures Hundreds of Millions in Series E Funding Led by Legend Capital and Qiming Venture Partners

VCBeat learned that recently, DK Medical Technology Co., Ltd. (hereinafter referred to as "DK Medtech") has completed a multi-million-yuan E-round financing. This round of financing was jointly led by Legend Capital and Qiming Venture Partners, with the angel round investor of DK Medtech also participating in the investment.The funds from this round of financing will be used to strengthen the manufacturing center and commercialization construction, further enhance DK Medtech's leading advantage in technology and product innovation, and simultaneously plan for overseas market investment and expansion.

DK Medtech was founded in 2015 and is a leading innovative enterprise in China that specializes in a full range of interventional balloons. The company has developed more than ten types of balloons, including standard balloons, high-pressure balloons, scoring balloons, and drug-coated scoring balloons. Its product line covers the needs of almost all vascular intervention fields, including cardiovascular intervention, peripheral intervention, and neurointervention. After years of development, DK Medtech has obtained 13 Class III medical device registration certificates and completed pre-market RCT clinical studies for five special types of balloons.

According to the "Blue Paper on the Status and Development Trends of the Special Balloon Industry in Vascular Intervention" released in March this year by Frost & Sullivan (hereinafter referred to as "Sullivan"), the technical development of special balloons is summarized in five stages: guidewire technology, cutting technology, hump technology, papillary technology, and scoring technology.

Currently, the vast majority of products named as scoring balloons use traditional metal wires as pressurized protrusions. However, DK Medtech has independently developed...Directional Scoring Technology，Using exclusive nickel-titanium winding technology to create cutting components, it combines metallic sharpness and flexibility, demonstrating excellent performance in expanding vascular stenosis lesions, and is distinctly different from other products.

According to the official product information released by DK Medtech, the patented technology for directional scoring is currently used in coronary scoring balloons, peripheral scoring balloons, and drug-coated scoring balloons. Moreover, based on the published pre-market RCT studies of these products, their clinical performance demonstrates significantly greater clinical benefits compared to imported control groups.

DK Medtech's coronary scoring balloon dilation catheter (Registration No. 20223031162), scoring balloon dilation catheter (Registration No. 20223031527), and peripheral scoring drug-coated balloon dilation catheter (Registration No. 20233030980) are all the first products in their respective categories to obtain certification.

Relying on the performance advantages of DK Medtech's products, the company has successfully advanced the commercialization of its product portfolio. In the field of hemodialysis access, DK Medtech’s balloon catheters have entered the first tier, offering a global solution for various types of balloons in this area, and establishing a general agency partnership with US-based Merit Medical for the LifeSpan artificial blood vessel. In the peripheral intervention field, DK Medtech unveiled the world’s largest-scale RCT study on special category balloons at the Leipzig Interventional Course (LINC2024) in Germany this May, achieving outstanding results that attracted significant attention from international experts. In the coronary balloon sector, the company has reached multiple strategic collaborations with Medtronic and Asahi Intecc, leveraging the mature marketing systems of these international giants to jointly promote domestically innovative products.

Founder of DK Medtech, Weng YulinStated: "The original intention of DK Medtech's entrepreneurship is to create distinctive high-quality products. Regardless of how policies and markets change, only by persisting in making products that truly address clinical pain points can we ensure the product's vitality and social value."

Mentioning this investment,Mr. Zhou Quan, Managing Director of Legend CapitalSaid: "DK Medtech meets clinical needs through independent research, development, innovation, and by analyzing and evaluating real clinical pain points.，BuildProducts that meet international first-class standards。DK Medtech's Technical R&D StrengthIs a domestically produced high-end medical device consumableRepresentative`, Company`According to the product features, a dual-track commercialization strategy was adopted for rapid commercial implementation. We highly recognize DK Medtech.TeamAndIts high efficiency"Execution ability, I am very honored to be able to work together with DK Medtech and develop together."

Mr. Zhang Ao, Executive Director of Qiming Venture Partners"In the process of our investment, DK Medtech has achieved many milestones. Both in terms of product line design and planning or commercial layout, they have demonstrated strategic thinking. We are optimistic about the future development of DK Medtech and look forward to the company growing into a leader in the interventional balloon field in the near future, evolving into a full technology platform specializing in precision balloons."

Legend Capital was founded in April 2001 and is a leading professional investment institution in China, focusing on early-stage venture capital and growth-stage private equity investment.

Over the course of more than two decades of development, Legend Capital has adhered to internationally recognized standards, managing several funds through complete cycles and delivering outstanding, sustainable fund performance. To date, it has cumulatively invested in over 600 companies, with 111 achieving IPO exits on various global capital markets and nearly 100 exiting through mergers and acquisitions. Among its portfolio companies are top-tier firms such as iFlytek, CATL, WuXi AppTec, and Pharmaron, as well as a large number of national-level specialized and innovative "little giant" enterprises and single-category manufacturing champions, creating a wealth of industry resources.

Legend Capital has always adhered to its original aspiration: to promote enterprise innovation and growth, and to drive industrial progress and social development through the help of capital and management. While achieving excellent performance, it actively fulfills its social responsibilities and strives for sustainable and high-quality development.

Qiming Venture Partners was founded in 2006. It currently manages 11 US dollar funds and 7 RMB funds, with total managed assets reaching 9.5 billion US dollars. Since its establishment, it has focused on investing in outstanding enterprises in the early and growth stages of the Technology and Consumer (T&C), and Healthcare industries.

As of now, Qiming Venture Partners has invested in more than 530 rapidly growing innovative enterprises, of which over 200 have gone public on exchanges such as the New York Stock Exchange, NASDAQ, Hong Kong Stock Exchange, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through mergers and acquisitions. More than 70 of these enterprises have become unicorns or super unicorns recognized within their industries.